|
|
|
| News | | |  |
| IDRI to Use NanoPass Microneedle Technology | |
Seattle, U.S.A and Nes Ziona, Israel – August 31, 2009
The Infectious Disease Research Institute (IDRI) and NanoPass Technologies Ltd. (NanoPass) today announced they have entered into an agreement whereby IDRI licenses NanoPass’ proprietary MicronJet microneedle technology for the intradermal delivery of products against a number of diseases including tuberculosis, HIV, malaria, leishmaniasis and leprosy, among others. The financial details of the agreement are confidential... READ MORE
|
| NanoPass Makes its MicronJet Technology Available to Increase Global Supply |
Nes Ziona, Israel, August 11, 2009
Intradermal delivery of vaccines can provide significant dose sparing urgently required in the swine H1N1 Pandemic.
Following the World Health Organization (WHO) declaration of a swine flu pandemic, NanoPass Technologies Ltd. (NanoPass) announced today that it has successfully developed a microneedle-based injection device that could dramatically enhance both the effectiveness and supply of pandemic flu vaccines....READ MORE
|
| Clinical Trials | |
March 16th 2009
NanoPass has completed a double-blinded proof of concept trial demonstrating effective, safe, and painless local anesthesia with the MicronJet.
January 1st 2009
NanoPass has completed a pilot clinical trial demonstrating the safety and efficacy of intradermal insulin injection in type 2 diabetics. Although not powered for superiority, shorter Tmax and higher Cmax were demonstrated with intradermal injection of insulin as compared to subcutaneous injection. While requiring further clinical data, faster absorption of insulin may shorten the lag timeassociated with insulin injection and improve therapy and compliance.
November 1st 2008
NanoPass has completed a clinical trial demonstrating that intradermal influenza vaccination with the MicronJet enables 80% dose reduction with equivalent immunogenicity as compared to standard intramascular vaccination. This 180 patient study, conducted in collaboration with the University of Anwerp's Vaccine & Infectious Disease Institute, has been recently published at Vaccine.
|
| Regulatory Affairs |
February 2010
NanoPass Recieves FDA clearance (510k) for the Micronjet needle
|
|
|
|
